Incyte Corporation is a biopharmaceutical company headquartered in Wilmington, Delaware, focused on discovering, developing, and commercializing innovative therapies in oncology and other serious diseases. Established in 1991, Incyte's commercial portfolio includes products such as Jakafi, a treatment for myelofibrosis and polycythemia vera, and its pipeline features numerous promising candidates targeting various malignancies. The company's strategic commitment to advancing precision medicine positions it as a significant player in the biopharma landscape, with robust research efforts aimed at addressing unmet medical needs. Incyte is dedicated to improving patient outcomes through scientific innovation and collaboration in the healthcare ecosystem.